摘要
目的 在炎症性肠病患者的治疗当中，应用益生菌联合美沙拉嗪治疗，探究其临床效果和症状消失时间。方法 在2019年5月~2021年5月期间，选取50名炎症性肠病患者参与本次对照试验，按照均等性原则与随机性原则对患者分组并分别进行美沙拉嗪治疗与益生菌联合美沙拉嗪共同治疗。通过炎症性肠病症状缓解时间、临床疗效以及症状消失时间对两种方法进行评定。结果 实验组经治疗后炎症性肠病症状缓解所用时长较短，治疗总有效率高达88.00%，症状消失时间约为4周，以上数据均优于对照组且达到了P<0.05标准。结论 美沙拉嗪联合益生菌治疗炎症性肠病可以起到明显疗效，缓解病症且缩短其症状消失时间。
关键词： 美沙拉嗪；益生菌；疗效；症状消失
Abstract
Objective In the treatment of patients with inflammatory bowel disease, probiotics combined with mesalazine were used to explore their clinical effects and time of disappearance of symptoms. Methods From May 2019 to May 2021, 50 patients with inflammatory bowel disease were selected to participate in this controlled trial, and the patients were grouped according to the principle of equality and randomness, and methazalazine treatment and probiotics combined with mesalazine were treated separately. Both methods were evaluated by the time of remission of inflammatory bowel disease symptoms, clinical efficacy, and time of disappearance of symptoms. Results The duration of the treatment of inflammatory bowel disease symptoms in the experimental group was short, the total effective rate of treatment was as high as 88.00%, and the disappearance time of symptoms was about 4 weeks, which was better than that of the control group and reached the P<0.05 standard. Conclusion Mesalazine combined with probiotics in the treatment of inflammatory bowel disease can play a significant role in shortening the time of remission and disappearance of the disease.
Key words： Mesalazine; Probiotics; Efficacy; Symptoms disappear
参考文献 References
[1] 范晓斐,李军. 美沙拉嗪联合益生菌对炎症性肠病的疗效及IL-10和TNF-α的影响[J]. 医药论坛杂志,2021,42(9):30-33,37.
[2] 朱细方.益生菌联合美沙拉嗪治疗炎症性肠病（IBD）的临床效果及安全性[J].吉林医学.2020,(2).356~357.
[3] 耿英.美沙拉嗪联合益生菌治疗炎症性肠病的疗效分析[J].中国继续医学教育.2020,(16).144~146.
[4] 尹娟.布拉酵母菌散联合美沙拉嗪肠溶片对活动期溃疡性结肠炎患者内镜检查评分及炎症因子的影响[J].中国药物与临床.2020,(12).2011~2013.
[5] 梁素花,张爱国,孟丽英,等.酪酸梭菌活菌胶囊与美沙拉嗪联合治疗炎性肠病的临床疗效[J].中国药物与临床.2019,(23).4134-4136.
[6] 陈春晓,曾长镜,邓冬梅.美沙拉嗪与益生菌联合治疗IBD患者的临床效果观察[J].当代医学.2019,(2).79-81.
[7] 李亚妮,李静绿.美沙拉嗪联合益生菌对炎症性肠病患者疗效及安全性的影响 [J].全科口腔医学杂志（电子版）,2019,6(1):160,166.
[8] 张爱华,杨琳娜.美沙拉嗪联合益生菌对炎症性肠病患者疗效及安全性的影响[J].首都食品与医药,2020,27(8):64.
[9] 李红纳,唐源,王凤纤.美沙拉嗪肠溶片联合益生菌对炎症性肠病的疗效及血清炎性因子的影响[J].智慧健康.2019,(13).146-147.
[10] 王红.美沙拉嗪与益生菌治疗炎症性肠病的临床疗效[J].航空航天医学杂志.2019,(4).398-399.
[11] 韩朝.益生菌联合美沙拉嗪对炎症性肠病患者的治疗效果[J].中国医药指南.2021,(5).59~60.
[12] 周立彬,凌彩苏,黄旭明.美沙拉嗪联合益生菌治疗炎症性肠病的疗效及安全性评价[J].反射疗法与康复医学.2021,2(15).
[13] 张士国.益生菌联合美沙拉嗪对炎症性肠病患者的治疗效果[J].中国医药指南.2021,(13).
[14] 廖罗罡睿.益生菌联合美沙拉嗪对炎症性肠病患者疗效研究[J].中国社区医师.2021,(16).